<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer - Wulaningsih, W - 2016 | Cochrane Library</title> <meta content="Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer - Wulaningsih, W - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008593.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer - Wulaningsih, W - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008593.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008593.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer" name="citation_title"/> <meta content="Wahyu Wulaningsih" name="citation_author"/> <meta content="wahyu.wulaningsih@kcl.ac.uk" name="citation_author_email"/> <meta content="Ardyan Wardhana" name="citation_author"/> <meta content="Johnathan Watkins" name="citation_author"/> <meta content="Naomi Yoshuantari" name="citation_author"/> <meta content="Dimitra Repana" name="citation_author"/> <meta content="Guy's and St Thomas' NHS Foundation Trust" name="citation_author_institution"/> <meta content="Mieke Van Hemelrijck" name="citation_author"/> <meta content="Faculty of Life Sciences and Medicine, King's College London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD008593.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/02/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008593.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008593.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008593.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alopecia [chemically induced]; Antimetabolites, Antineoplastic [adverse effects, therapeutic use]; Antineoplastic Agents, Phytogenic [adverse effects, therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Camptothecin [administration &amp; dosage, adverse effects, analogs &amp; derivatives]; Colorectal Neoplasms [*drug therapy, mortality, pathology]; Diarrhea [chemically induced]; Disease-Free Survival; Fluorouracil [administration &amp; dosage, adverse effects]; Irinotecan; Nausea [chemically induced]; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008593.pub3&amp;doi=10.1002/14651858.CD008593.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xsb6SJyC";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008593\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008593\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008593.pub3",title:"Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression\\u2010free survival in patients with advanced and/or metastatic colorectal cancer",firstPublishedDate:"Feb 12, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Colorectal Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008593.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008593.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008593.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008593.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008593.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008593.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008593.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008593.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008593.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008593.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1734 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008593.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-sec-0066"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-sec-0060"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/appendices#CD008593-sec-0071"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/table_n/CD008593StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/table_n/CD008593StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#CD008593-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Wahyu Wulaningsih</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#CD008593-cr-0003">Ardyan Wardhana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#CD008593-cr-0004">Johnathan Watkins</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#CD008593-cr-0005">Naomi Yoshuantari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#CD008593-cr-0006">Dimitra Repana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information#CD008593-cr-0007">Mieke Van Hemelrijck</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information/en#CD008593-sec-0079">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 February 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008593.pub3">https://doi.org/10.1002/14651858.CD008593.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008593-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008593-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008593-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008593-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008593-abs-0001" lang="en"> <section id="CD008593-sec-0001"> <h3 class="title" id="CD008593-sec-0001">Background</h3> <p>Chemotherapy is the treatment of choice in patients with advanced or metastatic colorectal cancer (CRC) where surgical resection of metastases is not an option. Both irinotecan (IRI) and fluoropyrimidines are often included in first‐ or second‐ line chemotherapy treatment regimens in such patients. However, it is not clear whether combining these agents is superior to irinotecan alone. </p> </section> <section id="CD008593-sec-0002"> <h3 class="title" id="CD008593-sec-0002">Objectives</h3> <p>To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second‐line settings. </p> </section> <section id="CD008593-sec-0003"> <h3 class="title" id="CD008593-sec-0003">Search methods</h3> <p>We searched the following electronic databases to identify randomized controlled trials: Cochrane Colorectal Cancer Group Specialised Register (January 13, 2016), Cochrane Central Register of Controlled Trials (CENTRAL)(The Cochrane Library Issue 12, 2016), Ovid MEDLINE (1950 to January 13, 2016), Ovid EMBASE (1974 to January 13, 2016), registers of controlled trials in progress, references cited in relevant publications and conference proceedings in related fields (BioMed Central and Medscape's Conference). The key authors or investigators of all eligible studies, and professionals in the field were contacted when necessary. The search from January 2016 identified one eligible study, an ongoing trial currently presented as an abstract, to be considered in an update of this review. </p> </section> <section id="CD008593-sec-0004"> <h3 class="title" id="CD008593-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) investigating the efficacy and safety of IRI chemotherapy combined with fluoropyrimidine compared with IRI alone for the treatment of patients with advanced CRC, regardless of treatment line settings. </p> </section> <section id="CD008593-sec-0005"> <h3 class="title" id="CD008593-sec-0005">Data collection and analysis</h3> <p>Study eligibility and methodological quality were assessed independently by the two authors, and any disagreement was solved by a third author. The data collected from the studies were reviewed qualitatively and quantitatively using the Cochrane Collaboration statistical software RevMan 5.3. </p> </section> <section id="CD008593-sec-0006"> <h3 class="title" id="CD008593-sec-0006">Main results</h3> <p>Five studies were included in this review with a total of 1,726 patients. The top‐up search resulted in an additional ongoing trial, the results of which have not been incorporated in this review. Among five included studies, no reduction in all‐cause mortality was observed in the combination arm, with a summary hazard ratio (HR) of 0.91 (95% CI: 0.81‐1.02). Longer progression‐free survival was observed in those treated with the combination chemotherapy (HR: 0.68, 95% CI: 0.53‐0.87), however, this result may have been driven by findings from the single first‐line treatment setting study.<br/> The quality of evidence for overall survival was low and for progression‐free survival was moderate, mainly due to study limitation from the lack of information on randomisation methods and allocation concealment.<br/> There were higher risks of toxicity outcomes grade 3 or 4 diarrhoea and grade 1 or 2 alopecia, and a lower risk of grade 3 or 4 neutropenia in controls compared to the invervention group. Evidence for toxicity has been assessed to be low to moderate quality. </p> </section> <section id="CD008593-sec-0007"> <h3 class="title" id="CD008593-sec-0007">Authors' conclusions</h3> <p>There was no overall survival benefit of the irinotecan and fluoropyrimidine treatment over irinotecan alone, thus both regimens remain reasonable options in treating patients with advanced or metastatic CRC. Given the low and moderate quality of the evidence, future studies with sufficient numbers of patients in each treatment arms are needed to clarify the benefit observed in progression‐free survival with combination irinotecan and fluoropyrimidines. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008593-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008593-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008593-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008593-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008593-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008593-abs-0003" lang="en"> <h3>Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer </h3> <p><b>Background:</b> </p> <p>Patients with inoperable colorectal cancer (CRC) are likely to receive chemotherapy drugs as their primary treatment. Irinotecan (IRI) and fluoropyrimidines are two such drugs widely used in this setting, either alone or as part of multi‐drug chemotherapy treatments. </p> <p><b>Objectives:</b> </p> <p>Currently, there is lack of evidence comparing the combination of IRI and fluoropyrimidine with IRI alone. Therefore it was the aim of this review to compare the two treatments for patients with inoperable advanced or metastatic CRC. </p> <p><b>Investigation and study characteristics:</b> </p> <p>We searched the literature on January 13, 2016. We identified five randomised controlled trials with a total of 1,726 patients comparing the combination of IRI and fluoropyrimidine with IRI alone. The search in January 2016 resulted in an additional ongoing trial, the results of which have not been incorporated in this review.<br/> This review compared IRI and fluoropyrimidine with IRI alone in terms of overall survival, progression‐free survival, toxicity, response rates and quality of life. </p> <p><b>Main results:</b> </p> <p>There is no evidence to suggest any superiority of the combination of IRI and fluoropyrimidine over IRI alone, but our results on overall survival are limited by the number of studies available to date. Longer progression‐free survival was seen from adding fluoropyrimidines to IRI. Based on current evidence, both the combination regimens and IRI alone seem equally effective for treating advanced or metastatic patients. Patients in the intervention arm were less likely to develop grade 3 or 4 diarrhea and grade 1 or 2 alopecia, and more likely to have grade 3 or 4 neutropenia, compared to patients receiving IRI alone. </p> <p><b>Quality of the evidence:</b> </p> <p>There was moderate quality evidence from these studies suggesting longer progression‐free survival from adding fluoropyrimidines to IRI. However, findings need to be confirmed by larger, high‐quality randomised clinical trials. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008593-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008593-sec-0066"></div> <h3 class="title" id="CD008593-sec-0067">Implications for practice</h3> <section id="CD008593-sec-0067"> <p>Given available data from clinical trials and large heterogeneity in reported findings, there is no evidence to suggest any superiority in OS of the combination of IRI and fluoropyrimidine over IRI alone. Patients in the combination arm were shown to have longer PFS, but the moderate quality of the evidence indicates the necessity to confirm findings from this review in clinical studies with adequate sample size to address potential subgroup effects. Risks of grade 3 or 4 diarrhea and grade 1 or 2 alopecia were higher in the intervention arm compared to in controls, whereas the risk of grade 3 or 4 neutropenia was higher in the control group. These different toxicity profiles indicate the need for further consideration when selecting a suitable treatment based on individual characteristics of the patients at baseline. </p> </section> <h3 class="title" id="CD008593-sec-0068">Implications for research</h3> <section id="CD008593-sec-0068"> <p>Despite the emergence of targeted therapies, IRI and fluoropyrimidine remain an important components of the regimens used in treating advanced and metastatic CRC. Therefore, more clinical trials with sufficient numbers of patients in each line of treatment are needed to confirm any benefit seen with regimens containing the combination of IRI and fluoropyrimidine for CRC treatment compared to those containing IRI alone. It would be of interest for trialists to assess both regimens in combination with more recent biological agents, and include other administration routes, in order to achieve optimal clinical benefits. The ongoing study in ‘Studies awaiting classification’ may alter the conclusions of the review once results are available and incorporated.This also calls for designs of RCT protocols that allow for an unbiased comparison between groups of patients receiving IRI with and without the addition of fluoropyrimidine. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008593-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008593-sec-0015"></div> <div class="table" id="CD008593-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IRI with fluoropyrimidines versus single agent IRI for advanced and/or metastatic colorectal cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>IRI with fluoropyrimidines versus single agent IRI for advanced and/or metastatic colorectal cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with advanced and/or metastatic colorectal cancer<br/> <b>Settings:</b> first‐ and second‐ line treatments<br/> <b>Intervention:</b> IRI with fluoropyrimidines </p> <p><b>Control:</b> Single agent IRI. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IRI with fluoropyrimidines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> (Death)<br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b> <br/> (40 to 48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.91</b> <br/> (0.81 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1728<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> <br/> (Disease progression)<br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 100</b> <br/> (74 to 88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.68</b> <br/> (0.53 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Grade 3/4 diarrhea</b> </p> <p>Follow‐up:</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.66</b> <br/> (0.51 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1179<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>213 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>140 per 1000</b> <br/> (109 to 181) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b> <br/> (94 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Grade 3/4 nausea</b> </p> <p>Follow‐up:</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.33</b> <br/> (0.07 to 1.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>209<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (3 to 77) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (2 to 52) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>HR:</b> Hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) and one level for imprecision (Lack of sufficient number of samples may have reduced the statistical power of the analysis)<br/> <sup>2</sup> Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) </p> <p><sup>3</sup> Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) </p> <p><sup>4</sup> Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) and one level for imprecision (Lack of sufficient number of samples may have reduced the statistical power of the analysis) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008593-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008593-sec-0016"></div> <section id="CD008593-sec-0017"> <h3 class="title" id="CD008593-sec-0017">Description of the condition</h3> <p>Colorectal cancer (CRC) is currently the third most commonly diagnosed cancer for men and the second most common for women, as well as a leading cause of death worldwide (<a href="./references#CD008593-bbs2-0020" title="FerlayJ , ShinHR , BrayF , FormanD , MathersC , ParkinDM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer2010;127(12):2893‐917. ">Ferlay 2010</a>). In the United States, it was estimated that 136,830 people (71,830 men and 65,000 women) were diagnosed with CRC and 50,310 died from the disease in 2014 (<a href="./references#CD008593-bbs2-0041" title="SiegelR , DeSantisS , JemalA . Colorectal Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians2014;64:104‐17. ">Siegel 2014</a>). Despite the higher incidence and mortality rates of CRC in more developed countries , these rates have been decreasing over the last two decades, particularly in the United States (<a href="./references#CD008593-bbs2-0027" title="JemalA , BrayF , Center MM, FerlayJ , WardE , FormanD . Global cancer statistics. CA: a cancer journal for clinicians2011;61(2):69‐90. ">Jemal 2011</a>; <a href="./references#CD008593-bbs2-0040" title="SiegelR , NaishadhamD , JemalA . Cancer statistics, 2013. CA: A Cancer Journal for Clinicians2013;63(1):11‐30. ">Siegel 2013</a>). Conversely, both CRC incidence and mortality have increased in less developed countries, largely owing to limited resources and inadequate healthcare infrastructure (<a href="./references#CD008593-bbs2-0014" title="Center MM, JemalA , SmithRA , WardE . Worldwide variations in colorectal cancer. CA: a cancer journal for clinicians2009;59(6):366‐78. ">Center 2009</a>). </p> <p>Early stage CRC is potentially curable by surgery (<a href="./references#CD008593-bbs2-0028" title="KuhryE , SchwenkW , GaupsetR , RomildU , BonjerJ . Long‐term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. Cancer Treatment Reviews2008;34(6):498‐504. ">Kuhry 2008</a>). However, 20‐25% of CRC patients are first diagnosed with metastatic disease, where curative surgical resection is unlikely to be carried out (<a href="./references#CD008593-bbs2-0041" title="SiegelR , DeSantisS , JemalA . Colorectal Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians2014;64:104‐17. ">Siegel 2014</a>; <a href="./references#CD008593-bbs2-0048" title="VanCutsemE , CervantesA , NordlingerB , ArnoldD , on behalf of the ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Annals of Oncology2014;25 (Supplement 3):iii1–iii9. ">Van Cutsem 2014</a>), and many patients relapse with metastatic disease after potentially curative resections. For these patients systemic chemotherapy is often the treatment of choice, with the objectives of relieving symptoms, increasing survival and improving quality of life (<a href="./references#CD008593-bbs2-0042" title="SimmondsPC . Palliative chemotherapy for advanced colorectal cancer: systematic review and meta‐analysis. Colorectal Cancer Collaborative Group. British Medical Journal2000;321(7260):531‐5. ">Simmonds 2000</a>; <a href="./references#CD008593-bbs2-0036" title="RagnhammarP , HafströmL , NygrenP , GlimeliusB . A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncologica2001;40(2‐3):282‐308. ">Ragnhammar 2001</a>). </p> </section> <section id="CD008593-sec-0018"> <h3 class="title" id="CD008593-sec-0018">Description of the intervention</h3> <p>Antimetabolite fluoropyrimidines have been the backbone of CRC chemotherapy for the past 40 years. For decades, treatment efficacy from fluorouracil (FU) monotherapy has been limited. The subsequent combination of 5‐fluorouracil (5‐FU) with leucovorin (LV), a reduced folate that increases thymidylate synthetase inhibition, was used to modulate effects of 5‐FU and improve its efficacy (<a href="./references#CD008593-bbs2-0010" title="Advanced Colorectal Cancer Meta‐Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Journal of Clinical Oncology1992;10(6):896‐903. ">ACCMAP 1992</a>). This combination has resulted in better response rates than 5‐FU alone for advanced CRC (<a href="./references#CD008593-bbs2-0044" title="ThirionP , MichielsS , PignonJP , BuyseM , BraudAC , CarlsonRW , et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta‐analysis. Journal of Clinical Oncology2004;22(18):3766‐75. ">Thirion 2004</a>) and remains the main component of most chemotherapy regimens in CRC, either as an intravenous (IV) bolus injection, infusion, or both (<a href="./references#CD008593-bbs2-0015" title="ChauI , NormanAR , CunninghamD , IvesonT , HillM , HickishT , et al. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. European Journal of Cancer2005;41(11):1551‐9. ">Chau 2005</a>; <a href="./references#CD008593-bbs2-0030" title="MaielloE , GebbiaV , GiulianiF , PaolettiG , GebbiaN , BorsellinoN , et al. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO2005;16 Suppl 4:iv56‐60. ">Maiello 2005</a>). </p> <p>Irinotecan is a semisynthetic derivative of the natural alkaloid camptothecin which inhibits topoisomerase I, thus impeding DNA uncoiling and leading to double‐stranded DNA breaks (<a href="./references#CD008593-bbs2-0026" title="HsiangYH , HertzbergR , HechtS , LiuLF . Camptothecin induces protein‐linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry1985;260(27):14873‐8. ">Hsiang 1985</a>). This drug was shown to have antitumour activity against CRC when administered intravenously alone in a first‐line setting, or as a second‐line regimen for patients with advanced CRC that is refractory to FU (<a href="./references#CD008593-bbs2-0017" title="ContiJA , KemenyNE , SaltzLB , HuangY , TongWP , ChouTC , et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. Journal of Clinical Oncology1996;14(3):709‐15. ">Conti 1996</a>; <a href="./references#CD008593-bbs2-0035" title="PitotHC , WenderDB , O'ConnellMJ , SchroederG , GoldbergRM , RubinJ , et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology1997;15(8):2910‐9. ">Pitot 1997</a>; <a href="./references#CD008593-bbs2-0037" title="RothenbergML , CoxJV , DeVoreRF , HainsworthJD , PazdurR , RivkinSE , et al. A multicenter, phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma. Cancer1999;85(4):786‐95. ">Rothenberg 1999</a>; <a href="./references#CD008593-bbs2-0038" title="RougierP , BugatR , DouillardJY , CulineS , SucE , BrunetP , et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy‐naive patients and patients pretreated with fluorouracil‐based chemotherapy. Journal of Clinical Oncology1997;15(1):251‐60. ">Rougier 1997</a>; <a href="./references#CD008593-bbs2-0039" title="RougierP , VanCutsemE , BajettaE , NiederleN , PossingerK , LabiancaR , et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352(9138):1407‐12. ">Rougier 1998</a>) </p> <p>In more recent years, a number of oral fluoropyrimidines such as capecitabine have become available. In addition to its more convenient use as an oral agent, capecitabine has been shown in clinical trials to have superior safety profiles compared to IV 5‐FU/LV with similar (non‐inferior) overall survival (OS), progression‐free survival (PFS) and time to progression (TTP) for patients with metastatic CRC (<a href="./references#CD008593-bbs2-0034" title="PetrelliF , CabidduM , BarniS . 5‐Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled‐analysis of randomized trials. Medical Oncology2012;29(2):1020‐9. ">Petrelli 2012</a>; <a href="./references#CD008593-bbs2-0047" title="VanCutsemE , HoffPM , HarperP , BukowskiRM , CunninghamD , DufourP , et al. Oral capecitabine vs intravenous 5‐fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. British Journal of Cancer2004;90(6):1190‐7. ">Van Cutsem 2004</a>). These encouraging results suggest that oral fluoropyrimidine agents may serve as a suitable alternative to IV agents for CRC chemotherapy treatment. However, when both treatment arms were combined with irinotecan (IRI), IV 5‐FU/LV regimens demonstrated longer PFS and less toxicity in metastatic CRC compared to capecitabine (<a href="./references#CD008593-bbs2-0031" title="MontagnaniF , ChiriattiA , LicitraS , AlibertiC , FiorentiniG . Differences in efficacy and safety between capecitabine and infusional 5‐fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. Clinical Colorectal Cancer2010;9(4):243‐7. ">Montagnani 2010</a>), and the combination of capecitabine and IRI is used less commonly now. </p> </section> <section id="CD008593-sec-0019"> <h3 class="title" id="CD008593-sec-0019">How the intervention might work</h3> <p>As a first‐line chemotherapeutic regimen for CRC, IV IRI alone was demonstrated to have comparable antitumour activity to 5‐FU/LV (<a href="./references#CD008593-bbs2-0013" title="CaoS , RustumYM . Synergistic antitumor activity of irinotecan in combination with 5‐fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Research2000;60(14):3717‐21. ">Cao 2000</a>, <a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>). Besides a different mechanism of action from 5‐FU, the lack of cross‐resistance of IRI to previous 5‐FU/LV treatment, as shown by its similar activity against untreated and 5‐FU‐pretreated CRC, is the rationale for combining it with fluoropyrimidines as first‐line therapy for this disease (<a href="./references#CD008593-bbs2-0038" title="RougierP , BugatR , DouillardJY , CulineS , SucE , BrunetP , et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy‐naive patients and patients pretreated with fluorouracil‐based chemotherapy. Journal of Clinical Oncology1997;15(1):251‐60. ">Rougier 1997</a>). The synergistic effects between IRI and fluoropyrimidines have been suggested to be comparable with that of IRI and oxaliplatin despite difference different toxicity profiles (<a href="./references#CD008593-bbs2-0016" title="ColucciG , GebbiaV , PaolettiG , GiulianiF , CarusoM , GebbiaN , Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia. Journal of Clinical Oncology2005;23:4866‐75. ">Colucci 2005</a>; <a href="./references#CD008593-bbs2-0046" title="TournigandC , AndréT , AchilleE , LledoG , FleshM , Mery‐MignardD , et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology2004;22:229‐37. ">Tournigand 2004</a>). As the second‐line treatment for advanced CRC, two phase III studies have shown modest benefits in survival with IRI of 2.3 months and 2.7 months compared to IV 5‐FU and best supportive care, respectively (<a href="./references#CD008593-bbs2-0039" title="RougierP , VanCutsemE , BajettaE , NiederleN , PossingerK , LabiancaR , et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352(9138):1407‐12. ">Rougier 1998</a>; <a href="./references#CD008593-bbs2-0018" title="CunninghamD , PyrhonenS , JamesRD , PuntCJ , HickishTF , HeikkilaR , et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet1998;352(9138):1413‐8. [PUBMED: 9807987] ">Cunningham 1998</a>). Until now, the superiority of IRI combined with fluoropyrimidines over fluoropyrimidines alone has been assumed and the combination regimen is now widely used for advanced CRC patients in clinical practice (<a href="./references#CD008593-bbs2-0019" title="DouillardJY , CunninghamD , RothAD , NavarroM , JamesRD , KarasekP , et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first‐line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355(9209):1041‐7. ">Douillard 2000</a>; <a href="./references#CD008593-bbs2-0029" title="MaielloE , GebbiaV , GiulianiF , PaolettiG , GebbiaN , CigolariS , et al. 5‐Fluorouracil and folinic acid with or without CPT‐11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Annals of Oncology2000;11(8):1045‐51. ">Maiello 2000</a>; <a href="./references#CD008593-bbs2-0021" title="FolprechtG , SeymourMT , SaltzL , DouillardJY , HeckerH , StephensRJ , et al. Irinotecan/fluorouracil combination in first‐line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. Journal of Clinical Oncology2008;26(9):1443‐51. ">Folprecht 2008</a>; <a href="./references#CD008593-bbs2-0023" title="GiessenC , vonWeikersthalLF , HinkeA , StintzingS , KullmannF , Vehling‐KaiserU , et al. A randomized, phase III trial of capecitabine plus bevacizumab (Cape‐Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI‐Bev) in first‐line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. BMC cancer2011;11:367. ">Giessen 2011</a>; <a href="./references#CD008593-bbs2-0032" title="MuroK , BokuN , ShimadaY , TsujiA , SameshimaS , BabaH , et al. Irinotecan plus S‐1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second‐line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non‐inferiority study (FIRIS study). The Lancet Oncology2010;11(9):853‐60. ">Muro 2010</a>). </p> </section> <section id="CD008593-sec-0020"> <h3 class="title" id="CD008593-sec-0020">Why it is important to do this review</h3> <p>Several randomized controlled trials (RCTs) comparing IRI in combination with fluoropyrimidines against IRI alone suggested that the combination regimen leads to better outcomes in OS and TTP for advanced CRC (<a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>; <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>), while the results of another trial and a meta‐analysis indicated that IRI monotherapy had equivalent efficacy and toxicity (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a>). However, the meta‐analysis comparing IRI and IV 5‐FU/LV combination regimen (FOLFIRI) for second‐line treatment of CRC was not specific for trials concurrently including both treatment arms (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>). Thus the benefit of IRI and fluoropyrimidines over IRI monotherapy remains unclear. Taking their efficacy and toxicity into account, we therefore undertook this study to systematically compare the combination regimen with IRI alone to determine which regimen is more suitable for advanced CRC patients, either as a first‐line or a second‐line therapy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008593-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008593-sec-0021"></div> <p>The aim of this systematic review was to compare the efficacy and safety of two chemotherapeutic regimens, IRI monotherapy or IRI in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second‐line setting. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008593-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008593-sec-0022"></div> <section id="CD008593-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008593-sec-0024"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) investigating the efficacy and safety of chemotherapeutic regimens that compared IRI combined with fluoropyrimidine against IRI alone for the treatment of patients with advanced CRC, regardless of treatment line settings, were eligible for the inclusion. If trials enrolled more than two groups, we only extracted data that related to the two regimens. Relevant cluster RCTs were eligible for this review. </p> </section> <section id="CD008593-sec-0025"> <h4 class="title">Types of participants</h4> <p>Studies involving patients diagnosed histologically or cytologically with locally advanced and/or metastatic CRC were included. </p> </section> <section id="CD008593-sec-0026"> <h4 class="title">Types of interventions</h4> <p>The experimental group received the combination regimen, namely IRI with fluoropyrimidines administered intravenously or orally; the control group received single agent IRI. Other agents were acceptable as long as they were common to both treatment arms, except LV, which is specific to IV 5‐FU. </p> </section> <section id="CD008593-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD008593-sec-0028"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome measures were:</p> <p> <ul id="CD008593-list-0001"> <li> <p>Overall survival (OS),</p> </li> <li> <p>Time to progression (TTP) or progression‐free survival (PFS)</p> </li> </ul> </p> <p>All outcomes were analysed on an intention to treat (ITT) basis. Studies which reported survival outcomes either directly or by curves were included, if the relevant data could be obtained by using Parmar methods (<a href="./references#CD008593-bbs2-0033" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. [PUBMED: 9921604] ">Parmar 1998</a>; <a href="./references#CD008593-bbs2-0045" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. [PUBMED: 17555582] ">Tierney 2007</a>). </p> </section> <section id="CD008593-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p>The secondary outcome measures were:</p> <p> <ul id="CD008593-list-0002"> <li> <p>toxicity, classified according to the National Cancer Institute Common Toxicity Criteria (NCI‐CTC version 2.0), </p> </li> <li> <p>response rates, classified according to the RECIST criteria (see below),</p> </li> <li> <p>quality of life, measured by the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ‐C30) </p> </li> </ul> </p> <p>Response rates were classified according to Response Evaluation Criteria In Solid Tumors (RECIST version 1.0) (<a href="./references#CD008593-bbs2-0043" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute2000;92(3):205‐16. ">Therasse 2000</a>), where measurable target and non‐target lesions were determined at baseline and evaluated during follow up. A complete response (CR) was defined as disappearance of full lesion, while partial response (PR) referred to a decrease of at least 30% of lesion and progressive disease (PD) an increase of at least 20% of the lesion. Those with insufficient changes to be categorized as either PR or PD were classified as stable disease (SD). CR and PR were used as outcomes in this review. </p> </section> </section> </section> <section id="CD008593-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed an updated search in January 2016, resulting in identification of an ongoing trial added to ‘Studies awaiting classification’. </p> <section id="CD008593-sec-0031"> <h4 class="title">Electronic searches</h4> <p>Published or unpublished trials eligible for inclusion were identified by performing searches in the following databases: </p> <p> <ul id="CD008593-list-0003"> <li> <p>Cochrane Colorectal Cancer Group Specialized Register (December 2014);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL)(The Cochrane Library Issue 12, 2014) (<a href="./appendices#CD008593-sec-0072">Appendix 1</a>); </p> </li> <li> <p>Ovid MEDLINE from 1950 to 8 December 2014 (<a href="./appendices#CD008593-sec-0073">Appendix 2</a>) </p> </li> <li> <p>Ovid EMBASE from 1974 to 8 December 2014 (<a href="./appendices#CD008593-sec-0074">Appendix 3</a>) </p> </li> <li> <p>Science Citation Index from 1900 to 8 December 2014 (<a href="./appendices#CD008593-sec-0075">Appendix 4</a>) </p> </li> </ul> </p> <p>In each database, both medical subject headings and free‐text searching were performed in order to improve the sensitivity of the searches. All above databases were searched from the beginning of electronic records to the time at which the search was conducted and eligible studies in both English and non‐English languages were identified without any publication date or publication status limitations. </p> </section> <section id="CD008593-sec-0032"> <h4 class="title">Searching other resources</h4> <p>Published meta‐analyses and relevant reviews, registers of controlled trials in progress (World Health Organization's International Clinical Trials Registry and ClinicalTrials.gov), references cited in relevant publications and conference proceedings in related fields were also searched (BioMed Central and Medscape's Conference). The key authors or investigators of all eligible studies, and professionals in the field were contacted if necessary in order to obtain other relevant information on the topic. In addition, bibliographies of identified trials and relevant references were hand‐searched. </p> </section> </section> <section id="CD008593-sec-0033"> <h3 class="title" id="CD008593-sec-0033">Data collection and analysis</h3> <section id="CD008593-sec-0034"> <h4 class="title">Selection of studies</h4> <p>The title, abstract and keywords of every record from retrieved studies obtained by applying the above search strategies were checked independently against the inclusion criteria by two reviewers (AW and NY). All eligible studies were included irrespective of whether measured outcome data were reported on. Disagreements were resolved by a third reviewer (WW). Potentially eligible trials were retrieved in full for further assessment. Where more than one publication of a single trial existed, only the publication with the most complete data was included unless the relevant outcomes were only published in earlier versions. </p> </section> <section id="CD008593-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Data was extracted from published papers independently by two reviewers (WW and NY). Any disagreement was resolved by a third reviewer (MVH). Data for overall survival and progression‐free survival was extracted from the publications or estimated from survival curves where necessary. The following data of each study was requested: response rates (complete and partial), toxicity, the outcomes of quality life measurements, if any, the schedule and dosing of IRI or fluoropyrimidines, and baseline characteristics including age, sex, performance status, site of metastatic disease, whether or not patients had received previous adjuvant chemotherapy, site of primary tumor (rectum versus colon). If a study did not include one of the comparators of interest, only available results on the other interventions were included. The investigators of included studies were asked to supply updated data where possible. </p> </section> <section id="CD008593-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The methodological quality of the included studies was evaluated independently by two reviewers (WW and AW) with disagreements resolved by a third reviewer (MVH) according to the Cochrane Handbook. For each study, the following domains were assessed (<a href="./references#CD008593-bbs2-0024" title="HigginsJPT , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , Cochrane Bias Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. British Medical Journal2011;343:d5928. ">Higgins 2011</a>): </p> <p> <ol id="CD008593-list-0004"> <li> <p>Selection bias: the generation of allocation schedule (truly random, quasi random, systematic) &amp; concealment of treatment allocation. </p> </li> <li> <p>Performance bias: blinding of study participants and personnel.</p> </li> <li> <p>Detection bias: blinding of outcome assessors.</p> </li> <li> <p>Attrition bias: completeness of follow‐up, withdrawal and drop‐out rates and whether analyses were performed by ITT. </p> </li> <li> <p>Selective outcome reporting: evidence that outcome data have been reported based on the nature of the results. </p> </li> <li> <p>Other biases, such as deviation from the study protocol in a way that does not reflect clinical practice. </p> </li> </ol> </p> <p>The methods and procedures within each domain were judged as low, high or unclear risk of bias based on criteria specified in the Cochrane Risk of Bias tool (see <a href="./appendices#CD008593-sec-0076">Appendix 5</a>)(<a href="./references#CD008593-bbs2-0024" title="HigginsJPT , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , Cochrane Bias Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. British Medical Journal2011;343:d5928. ">Higgins 2011</a>). Any disagreements were resolved by discussion between the reviewers. Investigators were contacted where this information could not be extracted from the publication. </p> </section> <section id="CD008593-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>The absolute effects of treatment at different time points were obtained from publication data or read from simple (non‐stratified) Kaplan Meier curves of included trials. Median survivals and TTP (or PFS) were also estimated from Kaplan‐Meier curves. </p> <p>The information on survival and progress from each study was summarised as a log hazard ratio (HR). When HRs were not reported, observed (O) and the log‐rank expected (E) number of events and variance (V) were calculated from the numbers of events and the numbers at risk at each time interval in published Kaplan‐Meier survival curves (<a href="./references#CD008593-bbs2-0033" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. [PUBMED: 9921604] ">Parmar 1998</a>; <a href="./references#CD008593-bbs2-0045" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. [PUBMED: 17555582] ">Tierney 2007</a>). These numbers were used to estimate the HRs for all time intervals. When estimates from Cox regression were reported, the HRs were included in the analysis instead of those manually derived from the log‐rank method (O‐E/V). The general inverse variance method was used to obtain summary log HRs from combined studies. </p> <p>All time to event analyses were performed by ITT.</p> </section> <section id="CD008593-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>For individual trials, the unit of analysis used was individual patients. For any eligible cluster RCTs, meta‐analysis was conducted based on results from analysis that took into account clustering design. For studies in which control of clustering was not performed or reported, and individual patient data was not available, the intervention effects of cluster RCT were corrected by reducing the size of each trial to its 'effective sample size', which is the number of original sample size divided by the 'design effect'. The design effect were calculated as 1 + (M‐1)* ICC, where M is the average cluster size and ICC is the intracluster correlation coefficient (<a href="./references#CD008593-bbs2-0025" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, March 2011. ">Higgins 2011b</a>). </p> </section> <section id="CD008593-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>All principal investigators of the selected trials were contacted and asked to provide data that were missing or information which could not be extracted from the publication. Among five authors contacted, two immediately complied, another two no longer had any data at hand, one did not respond. Fortunately, most of the authors whose additional information was unavailable have provided detailed survival data on their published papers. </p> </section> <section id="CD008593-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>The studies were evaluated clinically and methodologically to assess if it was reasonable to consider combining data. Statistical heterogeneity was measured by the visual inspection of the forest plots and statistically through an assessment of homogeneity based on the Chi<sup>2</sup> test for which a p‐value of less than 0.10 was considered an indication of substantial heterogeneity. The I<sup>2</sup> measurement was calculated as an indicator of the amount of statistical variation not attributable to sampling error. A value of more than 50% was considered to represent substantial heterogeneity. Where necessary, further investigations were undertaken to determine the source of the observed heterogeneity and in particular, whether there were any outlying studies driving this heterogeneity. Analyses were then conducted both with and without the outlying studies as part of a sensitivity analysis. </p> </section> <section id="CD008593-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots were visually inspected to assess publication bias. The presence of publication bias was indicated by an asymmetrical distribution of data points derived from HR estimates and standard errors of log HRs from individual studies in relation to the pooled estimate effect. </p> </section> <section id="CD008593-sec-0042"> <h4 class="title">Data synthesis</h4> <p>The statistical package Review Manager 5.3 (RevMan 5.3) provided by the Cochrane Collaboration was used for analysing data. For primary outcomes, pooled results on overall survival or progression‐free survival were expressed as HRs with 95% confidence intervals (CI) by calculating the overall HRs and its variance across the trials. A random effects model was used to address potential statistical heterogeneity among included studies. All time‐to‐event analyses were performed by ITT. </p> <p>For secondary outcomes, data on toxicity, response rates and quality of life, where available, were analysed as dichotomous data and the outcomes were reported as relative risks (RRs) with 95% CI. A Mantel‐Haenszel test was employed to obtain pooled estimates across studies under a random effects model. </p> </section> <section id="CD008593-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where different routes of administration were used, studies were grouped according to whether fluoropyrimidines were administered orally or intravenously. A second subgroup analysis was performed according to the different settings (first‐ or second‐line) under which individual trials were categorised. We also explored possible interactions between different methods of administration of 5‐FU in combination with IRI (infusion versus bolus) in order to investigate possible sources of heterogeneity. The Chi<sup>2</sup> test for interaction was used to test for consistency of effects across these subsets of trials. </p> </section> <section id="CD008593-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were performed in order to assess the robustness of our results to heterogeneity, different assumptions or methodological approaches: </p> <p> <ol id="CD008593-list-0005"> <li> <p>Removing studies at a high risk of bias in all domains assessed using the Cochrane Risk of Bias Tool </p> </li> <li> <p>Exclusion of studies that used other agents (in both study arms) that may affect treatment effects of study regimen. </p> </li> </ol> </p> <section id="CD008593-sec-0045"> <h5 class="title">Summary of findings</h5> <p>We evaluated the quality of evidence of the two primary outcomes (Overall survival and Progression‐free survival), and one secondary outcome (Toxicity) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and presented it in 'Summary of Findings' tables. </p> <p>The GRADE system classifies the quality of evidence in one of four grades:</p> <p> <ol id="CD008593-list-0006"> <li> <p>High: Further research is very unlikely to change our confidence in the estimate of effect; </p> </li> <li> <p>Moderate: Further research is likely to have an impact on our confidence in the estimate of effect and may change the estimate; </p> </li> <li> <p>Low: Further research is very likely to have an important impact on our confidence on the estimate og effect and is likely to change the estimate; or </p> </li> <li> <p>Very low: Any estimate of effect is very uncertain.</p> </li> </ol> </p> <p>The quality of evidence were to be downgraded by one (serious concern) or two levels (very serious concern) for the following reasons: risk of bias, inconsistency (unexplained heterogeneity, inconsistency of results), indirectness (indirect population, intervention, control, outcomes) and imprecision (wide confidence intervald, single trial). The quality could also be upgraded by one level due to large summary effect. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008593-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008593-sec-0046"></div> <section id="CD008593-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD008593-sec-0048"> <h4 class="title">Results of the search</h4> <p>We identified a total of 3,117 records through the electronic searches. After removing duplicates, a total of 2,006 records were left to be checked for eligibility, of which 1,997 studies were clearly irrelevant and thus excluded. The updated search in January 2016 resulted in one ongoing trial, which has been added to ‘Studies awaiting classification’ (<a href="./references#CD008593-bbs2-0009" title="BendellJC , TanBR , ReevesJA , XiongHQ , LaeufleR , ByrtekM , et al. STEAM: A randomized, open‐label, phase 2 trial of sequential and concurrent FOLFOXIRI‐bevacizumab (BEV) versus FOLFOX‐BEV for the first‐line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology2014;32:5s:suppl; abstr TPS3652. ">Bendell 2014</a>). We retrieved full text of the remaining 8 records for further assessment (<a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>; <a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a>; <a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>; <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>; <a href="./references#CD008593-bbs2-0006" title="FiorentiniG , AlibertiC , TilliM , MulazzaniL , GrazianoF , GiordaniP , et al. Intra‐arterial infusion of irinotecan‐loaded drug‐eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Research2013;33(11):5211. ">Fiorentini 2012</a>; <a href="./references#CD008593-bbs2-0007" title="MitchellEP , PiperdiB , LacoutureME , ShearerH , IannottiN , PillaiMV , et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second‐linetherapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation ProtocolWith Panitumumab) by KRAS status. Clinical Colorectal Cancer2011;10(4):333‐9. ">Mitchell 2011</a>; <a href="./references#CD008593-bbs2-0008" title="PopovI , JelicS , KrivokapicZ , MicevM , BabicD , ZdraleZ . What is the best sequence of chemotherapy in advanced colorectal cancer? Final results of a five‐arm study. Chemotherapy2006;52:20–2. ">Popov 2006</a>). We excluded 3 studies for reasons listed in the <a href="./references#CD008593-sec-0086" title="">Characteristics of excluded studies</a>. In total, 5 RCTs fulfilled the inclusion criteria (<a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>, <a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>, <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a>,<a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>, <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>). All included studies were individual trials and no relevant cluster RCTs were identified. The study flow diagram is shown in <a href="#CD008593-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD008593-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD008593-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD008593-sec-0049"> <h4 class="title">Included studies</h4> <p>Five studies were included in this review, and details on IRI and fluoropyrimidine regimens are presented in <a href="#CD008593-tbl-0002">Table 1</a>. A total of 1,726 patients were randomised: 686 in the IRI‐fluoropyrimidine combination group and 1,040 in the control group. Four of the studies administered IRI and the combination of IRI with fluoropyrimidine as a second‐line treatment (<a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>; <a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a>; <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>) and one study as a first‐line treatment (<a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>); all used 5‐FU IV as the fluoropyrimidine of choice in the combination arm. No additional chemotherapeutic agents apart from LV in the 5‐FU arm were used except in <a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>, where oxaliplatin was administered in both treatment arms in addition to IRI and 5FU/LV. <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a> compared three strategies of sequential chemotherapy, where a second‐line treatment with IRI was administered in the control group and the IRI and 5‐FU combination was used as a second‐line treatment in one of the intervention groups, both groups had previously been treated with 5‐FU as the first‐line drug of choice. Randomisation occurred prior to first‐line treatments and therefore, the numbers of patients actually assigned to the combination IRI + 5‐FU and IRI groups (185 and 356 patients, respectively) were lower than those at randomisation (365 and 710 patients, respectively). All randomised patients were included when combining results from time‐to‐event analyses. One study (<a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>) administered three treatment arms: IRI alone, 5‐FU/LV alone, and a combination of IRI and 5‐FU‐LV, but a comparison was only made between the latter two. ITT analyses were conducted in all studies. </p> <div class="table" id="CD008593-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chemotherapy agent(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Additional agent(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycle interval</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median overall survival (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Bécouarn 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 180 mg/m2 IV 90 min on Day 1</p> <p>5‐FU 400 mg/m2 IV bolus and 600 mg/m2 IV 22 hrs on Day 1,2,15,16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxaliplatin on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8 (6.4‐13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 200 mg/m2 IV 30 min on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxaliplatin on Day 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3 (9.8‐14.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Clarke 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 180 mg/m2 IV 90 min on Day 1</p> <p>5‐FU 400 mg/m2 IV bolus and 2400 mg/m2 IV 46 hrs on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4 (8.1‐18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 300‐350 mg/m2 IV 90 min on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2 (8.3‐13.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Graeven 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 80 mg/m2 IV 60 min on Day 1,8,15,22,29,36</p> <p>5‐FU 2000 mg/m2 IV 24 hrs on Day 1,8,15,22,29,36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5 (6.5‐13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 125 mg/m2 IV 30‐60 min on Day 1,8,15,22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7 (8‐12.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Saltz 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 125 mg/m2 IV 90 min on Day 1,8,15,22</p> <p>5‐FU 500 mg/m2 IV bolus on Day 1,8,15,22 and 5‐FU 425 mg/m2 IV bolus on Day 1‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 125 mg/m2 IV 90 min on Day 1,8,15,22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Seymour 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 180 mg/m2 IV 30 min on Day 1</p> <p>5‐FU 400 mg/m2 IV bolus and 2400 mg/m2 IV 46 hrs on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 350 mg/m2 IV 30‐90 min on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008593-sec-0050"> <h4 class="title">Excluded studies</h4> <p>Among the remaining three studies from the search, two trials did not have randomized allocations of IRI regimens and thus were excluded (<a href="./references#CD008593-bbs2-0007" title="MitchellEP , PiperdiB , LacoutureME , ShearerH , IannottiN , PillaiMV , et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second‐linetherapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation ProtocolWith Panitumumab) by KRAS status. Clinical Colorectal Cancer2011;10(4):333‐9. ">Mitchell 2011</a>; <a href="./references#CD008593-bbs2-0008" title="PopovI , JelicS , KrivokapicZ , MicevM , BabicD , ZdraleZ . What is the best sequence of chemotherapy in advanced colorectal cancer? Final results of a five‐arm study. Chemotherapy2006;52:20–2. ">Popov 2006</a>). One study was excluded because it used intra‐arterial administration of IRI‐loaded drug‐eluting beads (DEBIRI) instead of an IV or oral route (<a href="./references#CD008593-bbs2-0006" title="FiorentiniG , AlibertiC , TilliM , MulazzaniL , GrazianoF , GiordaniP , et al. Intra‐arterial infusion of irinotecan‐loaded drug‐eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Research2013;33(11):5211. ">Fiorentini 2012</a>). </p> </section> </section> <section id="CD008593-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias was assessed from the available information reported by the authors and summarised in the <a href="./references#CD008593-sec-0085" title="">Characteristics of included studies</a> section. This assessment is also presented as the risk of bias graph (<a href="#CD008593-fig-0002">Figure 2</a>) and risk of bias summary (<a href="#CD008593-fig-0003">Figure 3</a>). Randomisation technique was one of the main components of the assessment. All studies randomised their patients when allocating treatments. Except for <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>, randomisation took place prior to treatment with experimental and control regimens. Further details on risk of bias in included studies are as following. </p> <div class="figure" id="CD008593-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008593-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008593-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008593-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008593-sec-0052"> <h4 class="title">Allocation</h4> <p>The methods used for randomisation and allocation concealment were less explicit. Only two RCTs described the technique used for randomization, minimisation (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>). Allocation concealment was only clear for one study (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>), which conducted central randomisation by telephone, resulting in 20% of the studies to have shown low risk of selection bias based on allocation concealment and 40% based on randomisation methods (<a href="#CD008593-fig-0002">Figure 2</a>). </p> </section> <section id="CD008593-sec-0053"> <h4 class="title">Blinding</h4> <p>One trial was open label and therefore judged to have had high risk of bias (<a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>). Blinding of personnel or study participants was not reported in any of other included studies. No mention of blinding of outcome assessors was made in any publication. Hence, 20% of all studies had high risk of bias from the lack of blinding (<a href="#CD008593-fig-0002">Figure 2</a>). </p> </section> <section id="CD008593-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>A total of 15 patients withdrew from the studies <a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>; <a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a>; <a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>: 8 in the experimental group, 7 in the control group, and 2 had no mention of their allocated group. In <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>, 154 patients who failed first‐line treatment with 5‐FU did not receive the allocated combination of IRI + fluoropyrimidines and 302 did not receive allocated IRI as second‐line treatment. Except for two patients withdrawing from the study in <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a> and one patient that refused the use of their data after withdrawing from the study in <a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>, all patients were included in the analysis. No reason was reported for patient withdrawal in the <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a> study, hence we regarded this study to have unclear risk of attrition bias, Overall, this showed 80% of included trials to have low risk of attrition bias (<a href="#CD008593-fig-0002">Figure 2</a>). </p> </section> <section id="CD008593-sec-0055"> <h4 class="title">Selective reporting</h4> <p>Limited information on pre‐specified outcomes was found when assessing reporting bias in individual studies, however, most studies reported both significant and insignificant findings in their publications. <a href="#CD008593-fig-0004">Figure 4</a> shows the funnel plot for results on OS. From visual inspection, all data points representing the estimates and precision of individual studies fell within the triangle comprising 95% confidence interval of the pooled effect estimate, with larger and more precise studies occupying the top of the inverted funnel and smaller and less precise studies more diversely scattered at the bottom. Most smaller and less precise studies (<a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>; <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a>) reported positive results. Although an assymetrical funnel plot was shown, interpretation is hampered given the small number of studies. Therefore, more studies are needed to determine a true reporting bias. </p> <div class="figure" id="CD008593-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot for comparisons of overall survival" data-id="CD008593-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for comparisons of overall survival</p> </div> </div> </div> </section> <section id="CD008593-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were identified from the studies and thus we assessed all studies (100%) to have low risk of other bias. </p> </section> </section> <section id="CD008593-sec-0057"> <h3 class="title" id="CD008593-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD008593-tbl-0001"><b>Summary of findings for the main comparison</b> IRI with fluoropyrimidines versus single agent IRI for advanced and/or metastatic colorectal cancer</a> </p> <section id="CD008593-sec-0058"> <h4 class="title">1. Primary outcomes</h4> <p>The primary outcomes of this review were Overall Survival (OS) and Progression‐free Survival (PFS) </p> <p><b>1.1 Overall survival</b> </p> <p>As seen in <a href="#CD008593-tbl-0002">Table 1</a>, median OS ranged between 9.5‐15.4 months in the intervention arms across all studies, and between 10.7‐13.9 months in the control arms. When comparing efficacy, subgroup analyses was performed according to the line of treatment, although only one study was found for the first‐line treatment setting (<a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>). For OS, analysis of both subgroups combined failed to show any statistically significant difference in overall mortality risk between the combination IRI + 5‐FU regime and IRI monotherapy arms (<a href="#CD008593-fig-0005">Figure 5</a>) (HR 0.91, with 95% CI of 0.81 to 1.02). No heterogeneity within and between subgroups was observed. Results were downgraded from high to low due to study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) and imprecision (Lack of sufficient number of samples may have reduced the statistical power of the analysis) (<a href="./full#CD008593-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD008593-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Overall survival." data-id="CD008593-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Overall survival.</p> </div> </div> </div> <p><b>1.2 Progression‐free survival</b> </p> <p>Three studies provided data on PFS (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a>; <a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>). An increase in progression‐free survival was seen in the combination IRI + 5‐FU arm overall, with a hazard ratio of 0.68 (95% CI: 0. 53‐0.87). Overall, no substantial heterogeneity was found (I<sup>2</sup> = 13%), and the difference between subgroups failed to reach significance (p=0.13). Nevertheless, results may have been largely driven by the study with first‐line setting (<a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>), and the summary HR for second‐line treatments showed no difference in risk of disease progression between the experimental and control group (<a href="#CD008593-fig-0006">Figure 6</a>). This finding was downgraded from high to moderate due to study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) (<a href="./full#CD008593-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD008593-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Progression‐free survival" data-id="CD008593-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Progression‐free survival</p> </div> </div> </div> </section> <section id="CD008593-sec-0059"> <h4 class="title">2. Secondary outcomes</h4> <p><b>2.1 Response to treatment</b> </p> <p>Response rates to treatment in the two arms were compared, which included CR and PR as the outcome of interest. No difference was observed with all studies combined. Individually or second‐line treatments by themselves (<a href="#CD008593-fig-0007">Figure 7</a>), first‐line treatment with the combination IRI + 5‐FU chemotherapy were shown to result in higher response rates (RR for CR and PR: 2.18 (95% CI: 1.50‐3.02)) compared to the controls. However, there was substantial heterogeneity overall (I<sup>2</sup> &gt; 50%). We therefore performed a sensitivity analysis in which we excluded a study with an additional chemotherapeutic agent in both arms (<a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>), which may have introduced bias. Re‐running the random effects model with this study excluded eliminated the overall heterogeneity and yielded a summary RR of 1.77 (95% CI: 1.32‐2.39; results not shown in figures), indicating better responses to treatment in the intervention arm compared to controls. </p> <div class="figure" id="CD008593-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Response to treatment (CR + PR)" data-id="CD008593-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Response to treatment (CR + PR)</p> </div> </div> </div> <p><b>2.2 Toxicity</b> </p> <p>Toxicity profiles were reported in both first‐ and second‐line treatments and combined, where information on individual toxicities was available. For grade 3/4 diarrhoea, a reduced overall risk was observed in the combination IRI + 5‐FU arm (RR: 0.66 (95% CI: 0.48‐0.91) compared to the controls (<a href="#CD008593-fig-0008">Figure 8</a>). A similar risk reduction was seen for grade 1/2 alopecia (RR: 0.45 (95% CI: 0.28‐0.74), while an increased risk of grade 3/4 neutropenia was observed in the experimental group (RR: 1.98 (95% CI: 1.48‐2.67) compared to the IRI arm. No marked difference was seen for other toxicities including grade 3 or 4 mucositis, nausea, and vomiting, and neuropathy (<a href="#CD008593-fig-0009">Figure 9</a>; <a href="#CD008593-fig-0010">Figure 10</a>; <a href="#CD008593-fig-0011">Figure 11</a>; <a href="#CD008593-fig-0012">Figure 12</a>; <a href="#CD008593-fig-0013">Figure 13</a>; <a href="#CD008593-fig-0014">Figure 14</a>; <a href="#CD008593-fig-0015">Figure 15</a>). For grade 1 or 2 alopecia and neuropathy, only estimates from 2 studies were available. However, a decision to pool the results was made based on similar treatment arms. No marked heterogeneity was found unless for analysis of grade 3 or 4 neutropenia (I<sup>2</sup>: 48%). A sensitivity analysis for grade 3 or 4 neutropenia excluding a study by <a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>, which included oxaliplatin in both treatment arms, revealed less heterogeneity without altering the findings (RR: 1.79 (95% CI: 1.49‐2.28); I<sup>2</sup>: 28%, results not shown in figures). Summary of findings table 2showed downgrading of evidence for toxicity outcomes grade 3/4 diarrhea to moderate due to study limitation, and grade 3/4 nausea to low due to study limitations and imprecision. </p> <div class="figure" id="CD008593-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Grade 3/4 diarrhea" data-id="CD008593-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Grade 3/4 diarrhea</p> </div> </div> </div> <div class="figure" id="CD008593-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Grade 3/4 mucositis" data-id="CD008593-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Grade 3/4 mucositis</p> </div> </div> </div> <div class="figure" id="CD008593-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Grade 3/4 nausea" data-id="CD008593-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Grade 3/4 nausea</p> </div> </div> </div> <div class="figure" id="CD008593-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Grade 3/4 vomiting" data-id="CD008593-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Grade 3/4 vomiting</p> </div> </div> </div> <div class="figure" id="CD008593-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Grade 3/4 neutropenia" data-id="CD008593-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Grade 3/4 neutropenia</p> </div> </div> </div> <div class="figure" id="CD008593-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Febrile neutropenia" data-id="CD008593-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Febrile neutropenia</p> </div> </div> </div> <div class="figure" id="CD008593-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Grade 1/2 alopecia" data-id="CD008593-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Grade 1/2 alopecia</p> </div> </div> </div> <div class="figure" id="CD008593-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Neuropathy" data-id="CD008593-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Neuropathy</p> </div> </div> </div> <p><b>2.3 Quality of life</b> </p> <p>Quality of life was assessed in three studies (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>; <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>). However, no detailed results were reported to enable a meta‐analysis. Findings varied for comparisons of overall quality of life between the experimental and control arms. <a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a> reported higher global health status for the combination IRI and 5‐FU regimen, although these results were not statistically significant. On the contrary, <a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a> showed a statistically significant lower overall quality of life with the combination chemotherapy. No benefit or disadvantage was observed between the two groups in <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008593-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008593-sec-0060"></div> <section id="CD008593-sec-0061"> <h3 class="title" id="CD008593-sec-0061">Summary of main results</h3> <p>Five studies fulfilled the inclusion criteria and were included in this review. High risk of bias due to the lack of blinding was seen with the <a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a> study. Low risk of selection bias based on allocation concealment was shown in one study (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>), whereas low risk based on randomisation techniques was seen in two studies (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>). There was a lack of sufficient information to fully assess other sources of bias. Overall, no OS benefit was seen by combining IRI with fluoropyrimidine for treating advanced or metastatic CRC compared to using IRI alone. Longer PFS and higher response rates were seen in the combination IRI + 5‐FU arms. However, these results may have been driven by the single first‐line treatment study, and for treatment response rates there was substantial heterogeneity. Toxicity profiles were different, with higher risks of grade 3 or 4 diarrhoea and grade 1 or 2 alopecia and a lower risk of grade 3 or 4 neutropenia in the control group compared to the combination arm. No conclusive results were available for quality of life. </p> </section> <section id="CD008593-sec-0062"> <h3 class="title" id="CD008593-sec-0062">Overall completeness and applicability of evidence</h3> <p>Overall, our findings indicate no clinical advantage of the combination of IRI and fluoropyrimidine treatment over IRI alone for patients with advanced or metastatic CRC, but our results were limited by the number of studies available for each treatment line. The significant heterogeneity between first‐ and second‐ line groups indicate that results may only be interpreted with respect to treatment settings. </p> </section> <section id="CD008593-sec-0063"> <h3 class="title" id="CD008593-sec-0063">Quality of the evidence</h3> <p>The quality of evidence in this review was classified as low and moderate (<a href="./full#CD008593-tbl-0001">summary of findings Table for the main comparison</a>). This was mostly due to high risk of bias assessed through the meta‐analysis and imprecision of results due to a lack of statistical power. When substantial heterogeneity was found such as in the assessment of response rates, lthough it was likely that the line of treatment is the major determinant of this heterogeneity, the plausible mechanism underlying the different effects on survival with respect to treatment setting is unclear. It is possible that treatment setting is a proxy of other prognostic factors in advanced or metastatic CRC, and therefore the observed heterogeneity reflects the difference in population characteristics rather than the interventions. Additionally, the small numbers of participants and a lack of studies with first‐line settings as mentioned above may indicate the necessity of confirming our findings through larger clinical studies sufficiently addressing each line of treatment. </p> </section> <section id="CD008593-sec-0064"> <h3 class="title" id="CD008593-sec-0064">Potential biases in the review process</h3> <p>The inclusion of randomised studies comprising first‐ and second‐line treatments strengthened this current review. However, even though similar drugs and routes of administration were used in all the included studies, there was variation in dosage and timings that may have affected the overall findings. Nevertheless, several studies suggested similar efficacy in treating advanced and metastatic CRC across IRI‐based regimens with different intervals of IRI administration (<a href="./references#CD008593-bbs2-0011" title="ArandaE , ValladaresM , Martinez‐VillacampaM , BenavidesM , GomezA , MassuttiB , et al. Randomized study of weekly irinotecan plus high‐dose 5‐fluorouracil (FUIRI) versus biweekly irinotecan plus 5‐fluorouracil/leucovorin (FOLFIRI) as first‐line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Annals of Oncology2009;20(2):251‐7. ">Aranda 2009</a>; <a href="./references#CD008593-bbs2-0012" title="BouzidK , KhalfallahS , TujakowskiJ , PikoB , PurkalneG , PlateS , et al. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5‐fluorouracil and folinic acid regimens as first‐line therapy for advanced colorectal cancer. Annals of Oncology2003;14(7):1106‐14. ">Bouzid 2003</a>), although further investigations are needed to delineate the impact of administration routes and other agents in combination with IRI. Additionally, only 5‐FU‐based regimens represented the fluoropyrimidine arm in this review. As differences in clinical outcomes have been reported with different fluoropyrimidine agents in IRI‐based regimens (<a href="./references#CD008593-bbs2-0022" title="FuchsCS , MarshallJ , MitchellE , WierzbickiR , GanjuV , JefferyM , et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first‐line treatment of metastatic colorectal cancer: results from the BICC‐C Study. Journal of Clinical Oncology2007;25(30):4779‐86. ">Fuchs 2007</a>), this may limit the generalisability of our findings.<br/> In the study conducted by Seymour and colleagues (<a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>), a sequential strategy was employed in which allocation to both first‐ and second‐line chemotherapy was performed at the start of the study. Patient eligibility was assessed prior to first‐line of treatment and this may have explained the high proportions of patients who did not receive the allocated second‐line treatments after failure in the first‐line setting. Insufficient patients may also have limited the results of this review, since a number of analyses had hazard ratios with wide CI<i>.</i> However, this is not likely the case for OS since a consistency between subgroups with first‐ and second‐line treatments was observed. For PFS and response rates, the benefit in the combination group was affected by inclusion of the first‐line treatment setting study (<a href="./references#CD008593-bbs2-0004" title="SaltzLB , CoxJV , BlankeC , RosenLS , FehrenbacherL , MooreMJ , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine2000;343(13):905‐14. ">Saltz 2000</a>). Since marked heterogeneity between subgroups was found, this signified the importance of conducting subgroup analyses based on first‐ or second‐line treatments. Such individualised interpretation may also be more useful when translating these findings to clinical context. Through the sensitivity analyses, we observed that including studies with an additional agent in both arms (oxaliplatin in this case) (<a href="./references#CD008593-bbs2-0001" title="BécouarnY , GamelinE , CoudertB , Ne´grierS , PiergaJY , RaoulJL , et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil‐pretreated metastatic colorectal cancer patients. Journal of Clinical Oncology2001;19(22):4195‐201. ">Bécouarn 2001</a>) increased heterogeneity in the final analyses. The different associations observed in presence of common additional agents, i.e. oxaliplatin, suggest that great care should be made when designing studies and choosing statistical methods to compare IRI with and without fluoropyrimidine where additional chemotherapeutic or biological agents are used. Finally, the fact that one ongoing study from the additional search have not yet been incorporated may be a source of potential bias. </p> </section> <section id="CD008593-sec-0065"> <h3 class="title" id="CD008593-sec-0065">Agreements and disagreements with other studies or reviews</h3> <p>A similar review was published in 2011, focusing on the use of IRI and 5‐FU compared to IRI alone as a second‐line treatment for advanced or metastatic CRC (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>), which included three studies that were also selected here (<a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>; <a href="./references#CD008593-bbs2-0003" title="GraevenU , ArnoldD , Reinacher‐SchickA , HeuerT , NuschA , PorschenR , et al. A randomised phase II study of irinotecan in combination with 5‐FU/FA compared with irinotecan alone as second‐line treatment of patients with metastatic colorectal carcinoma. Onkologie2007;30(4):169‐74. ">Graeven 2007</a>; <a href="./references#CD008593-bbs2-0005" title="SeymourMT , MaughanTS , LedermannJA , TophamC , JamesR , GwytherSJ , et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;30(9582):143‐52. ">Seymour 2007</a>). In this previous review, there was no significant benefit or disadvantage in OS or PFS by adding 5‐FU to IRI, which was similar to what we found for the second‐line treatment setting. In the current review, comparisons of toxicities were performed only for studies providing toxicity profiles of both experimental and control arms in both first‐ and second‐line treatments instead of combining results from single‐arm trials. Interestingly, for grade 3 or 4 diarrhea and grade 1 or 2 alopecia, the findings presented here were similar to that obtained from the single‐arm studies in <a href="./references#CD008593-bbs2-0002" title="ClarkeSJ , YipS , BrownC , vanHazelGA , RansomDT , GoldsteinD , et al. Single‐agent irinotecan or FOLFIRI as second‐line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta‐analysis [corrected]. European Journal of Cancer2011;47(12):1826‐36. ">Clarke 2011</a>, with higher risks observed in the single IRI arm. We also observed an increased risk of grade 3 or 4 neutropenia in the experimental arm. This may occur because neutropenia is a well‐known adverse effect of both IRI and 5‐FU. o Nevertheless, no difference in febrile neutropenia was observed between treatment arms. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008593-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD008593-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008593-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008593-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for comparisons of overall survival" data-id="CD008593-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot for comparisons of overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Overall survival." data-id="CD008593-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Progression‐free survival" data-id="CD008593-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Response to treatment (CR + PR)" data-id="CD008593-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Response to treatment (CR + PR)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Grade 3/4 diarrhea" data-id="CD008593-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Grade 3/4 diarrhea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Grade 3/4 mucositis" data-id="CD008593-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Grade 3/4 mucositis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Grade 3/4 nausea" data-id="CD008593-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Grade 3/4 nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Grade 3/4 vomiting" data-id="CD008593-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Grade 3/4 vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Grade 3/4 neutropenia" data-id="CD008593-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Grade 3/4 neutropenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Febrile neutropenia" data-id="CD008593-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Febrile neutropenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Grade 1/2 alopecia" data-id="CD008593-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Grade 1/2 alopecia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Neuropathy" data-id="CD008593-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Neuropathy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall Survival, Outcome 1 Overall survival." data-id="CD008593-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Overall Survival, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall Survival, Outcome 2 Overall survival." data-id="CD008593-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Overall Survival, Outcome 2 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progression‐Free Survival, Outcome 1 Progression‐free survival." data-id="CD008593-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Progression‐Free Survival, Outcome 1 Progression‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Response to Treatment, Outcome 1 Objective response (CR + PR)." data-id="CD008593-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Response to Treatment, Outcome 1 Objective response (CR + PR).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 1 Grade 3/4 diarrhea." data-id="CD008593-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 1 Grade 3/4 diarrhea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 2 Grade 3/4 mucositis." data-id="CD008593-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 2 Grade 3/4 mucositis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 3 Grade 3/4 nausea." data-id="CD008593-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 3 Grade 3/4 nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 4 Grade 3/4 vomiting." data-id="CD008593-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 4 Grade 3/4 vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 5 Grade 3/4 neutropenia." data-id="CD008593-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 5 Grade 3/4 neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 6 Febrile neutropenia." data-id="CD008593-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 6 Febrile neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 7 Grade 1/2 alopecia." data-id="CD008593-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 7 Grade 1/2 alopecia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 8 Neuropathy." data-id="CD008593-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 8 Neuropathy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008593-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/urn:x-wiley:14651858:media:CD008593:CD008593-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_t/tCD008593-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Toxicity, Outcome 9 Grade 3/4 anemia." data-id="CD008593-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Toxicity, Outcome 9 Grade 3/4 anemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/media/CDSR/CD008593/image_n/nCD008593-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008593-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IRI with fluoropyrimidines versus single agent IRI for advanced and/or metastatic colorectal cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>IRI with fluoropyrimidines versus single agent IRI for advanced and/or metastatic colorectal cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with advanced and/or metastatic colorectal cancer<br/> <b>Settings:</b> first‐ and second‐ line treatments<br/> <b>Intervention:</b> IRI with fluoropyrimidines </p> <p><b>Control:</b> Single agent IRI. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IRI with fluoropyrimidines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> (Death)<br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b> <br/> (40 to 48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.91</b> <br/> (0.81 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1728<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> <br/> (Disease progression)<br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 100</b> <br/> (74 to 88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.68</b> <br/> (0.53 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Grade 3/4 diarrhea</b> </p> <p>Follow‐up:</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.66</b> <br/> (0.51 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1179<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>213 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>140 per 1000</b> <br/> (109 to 181) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b> <br/> (94 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Grade 3/4 nausea</b> </p> <p>Follow‐up:</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.33</b> <br/> (0.07 to 1.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>209<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (3 to 77) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (2 to 52) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>HR:</b> Hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) and one level for imprecision (Lack of sufficient number of samples may have reduced the statistical power of the analysis)<br/> <sup>2</sup> Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) </p> <p><sup>3</sup> Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) </p> <p><sup>4</sup> Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open‐label intervention) and one level for imprecision (Lack of sufficient number of samples may have reduced the statistical power of the analysis) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IRI with fluoropyrimidines versus single agent IRI for advanced and/or metastatic colorectal cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008593-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chemotherapy agent(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Additional agent(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycle interval</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median overall survival (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Bécouarn 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 180 mg/m2 IV 90 min on Day 1</p> <p>5‐FU 400 mg/m2 IV bolus and 600 mg/m2 IV 22 hrs on Day 1,2,15,16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxaliplatin on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8 (6.4‐13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 200 mg/m2 IV 30 min on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxaliplatin on Day 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3 (9.8‐14.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Clarke 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 180 mg/m2 IV 90 min on Day 1</p> <p>5‐FU 400 mg/m2 IV bolus and 2400 mg/m2 IV 46 hrs on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4 (8.1‐18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 300‐350 mg/m2 IV 90 min on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2 (8.3‐13.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Graeven 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 80 mg/m2 IV 60 min on Day 1,8,15,22,29,36</p> <p>5‐FU 2000 mg/m2 IV 24 hrs on Day 1,8,15,22,29,36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5 (6.5‐13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 125 mg/m2 IV 30‐60 min on Day 1,8,15,22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7 (8‐12.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Saltz 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 125 mg/m2 IV 90 min on Day 1,8,15,22</p> <p>5‐FU 500 mg/m2 IV bolus on Day 1,8,15,22 and 5‐FU 425 mg/m2 IV bolus on Day 1‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 125 mg/m2 IV 90 min on Day 1,8,15,22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Seymour 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 180 mg/m2 IV 30 min on Day 1</p> <p>5‐FU 400 mg/m2 IV bolus and 2400 mg/m2 IV 46 hrs on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRI 350 mg/m2 IV 30‐90 min on Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/full#CD008593-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008593-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall Survival</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.81, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 First‐line treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Second‐line treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.75, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall Survival</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008593-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progression‐Free Survival</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.53, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 First‐line treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.45, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Second‐line treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progression‐Free Survival</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008593-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Response to Treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Objective response (CR + PR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.80, 2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 First‐line treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.58, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Second‐line treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.50, 1.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Response to Treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008593-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Toxicity</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Grade 3/4 diarrhea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Grade 3/4 mucositis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.45, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Grade 3/4 nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.07, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Grade 3/4 vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.47, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Grade 3/4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.29, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.53, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Grade 1/2 alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.28, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Neuropathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.27, 5.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Grade 3/4 anemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.08, 5.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Toxicity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008593.pub3/references#CD008593-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008593.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008593-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008593-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD008593-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008593\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008593\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008593\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008593\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008593\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008593.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008593.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008593.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008593.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008593.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727571405"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008593.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727571409"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008593.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eaf52ae3ff573',t:'MTc0MDcyNzU3MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 